Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

Video

In Partnership With:

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Findings from the APHINITY trial led to the 2017 FDA approval of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive breast cancer who are at high risk for recurrence. The overall survival data from this trial are still maturing, which means that questions remain.

Gorantla raises the question of managing patients with residual disease. Additionally, he asks, what should be done for patients who received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab, and pertuzumab?

Long-term implications also need to be considered, as well as the cost of therapy. Cost involves not only physical and emotional toxicities, Gorantla explains, but also financial toxicities. That is something that is being closely examined now. As for physical toxicities, the biggest issue with pertuzumab was the rate of diarrhea—approximately a 7% increase compared with trastuzumab alone—but it can be easily managed, Gorantla says.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute